Association between red cell distribution width and response to methotrexate in rheumatoid arthritis. 2020

M Bellan, and D Soddu, and E Zecca, and A Croce, and R Bonometti, and R Pedrazzoli, and D Sola, and C Rigamonti, and L M Castello, and G C Avanzi, and M Pirisi, and P P Sainaghi
Department of Translational Medicine, Università del Piemonte Orientale UPO, Novara, Italy; Division of Internal Medicine, Immunorheumatology Unit, CAAD (Center for Translational Research on Autoimmune and Allergic Disease) Maggiore della Carità Hospital, Novara, Italy; IRCAD, Interdisciplinary Research Center of Autoimmune Diseases, Novara. mattia.bellan@med.uniupo.it.

Red cell distribution width (RDW) is an unconventional biomarker of inflammation. We aimed to explore its role as a predictor of treatment response in rheumatoid arthritis (RA). Eighty-two RA patients (55 females), median age [interquartile range] 63 years [52-69], were selected by scanning the medical records of a rheumatology clinic, to analyze the associations between baseline RDW, disease activity scores and inflammatory markers, as well as the relationship between RDW changes following methotrexate (MTX) and treatment response. The lower the median baseline RDW, the greater were the chances of a positive EULAR response at three months, 13.5% [13.0-14.4] being among those with good response, vs 14.0% [13.2-14.7] and 14.2% [13.5- 16.0] (p=0.009) among those with moderate and poor response, respectively. MTX treatment was followed by a significant RDW increase (p<0.0001). The increase of RDW was greater among patients with good EULAR response, becoming progressively smaller in cases with moderate and poor response (1.0% [0.4-1.4] vs. 0.7 [0.1-2.0] vs. 0.3 [-0.1-0.8]; p=0.03). RDW is a strong predictor of early response to MTX in RA. RDW significantly increases after MTX initiation in parallel to treatment response, suggesting a role as a marker of MTX effectiveness.

UI MeSH Term Description Entries
D008297 Male Males
D008727 Methotrexate An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA. Amethopterin,Methotrexate Hydrate,Methotrexate Sodium,Methotrexate, (D)-Isomer,Methotrexate, (DL)-Isomer,Methotrexate, Dicesium Salt,Methotrexate, Disodium Salt,Methotrexate, Sodium Salt,Mexate,Dicesium Salt Methotrexate,Hydrate, Methotrexate,Sodium, Methotrexate
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D004909 Erythrocyte Indices ERYTHROCYTE size and HEMOGLOBIN content or concentration, usually derived from ERYTHROCYTE COUNT; BLOOD hemoglobin concentration; and HEMATOCRIT. The indices include the mean corpuscular volume (MCV), the mean corpuscular hemoglobin (MCH), and the mean corpuscular hemoglobin concentration (MCHC). Erythrocyte Hemoglobin, Mean Cell,Erythrocyte Size Determination,Erythrocyte Volume, Mean Cell,Hemoglobin, Erythrocyte, Mean Cell,Mean Corpuscular Volume,Red Cell Indices,Erythrocyte Diameter,Erythrocyte Index,Erythrocyte Indexes,Erythrocyte Thickness,Mean Cell Hemoglobin Concentration,Mean Cell Volume,Mean Corpuscular Hemoglobin,Mean Corpuscular Hemoglobulin Concentration,Red Cell Distribution Width,Red Cell Index,Red Cell Indexes,Cell Volumes, Mean,Corpuscular Volumes, Mean,Determination, Erythrocyte Size,Determinations, Erythrocyte Size,Diameter, Erythrocyte,Diameters, Erythrocyte,Erythrocyte Diameters,Erythrocyte Size Determinations,Hemoglobin, Mean Corpuscular,Hemoglobins, Mean Corpuscular,Index, Erythrocyte,Index, Red Cell,Indexes, Erythrocyte,Indexes, Red Cell,Indices, Erythrocyte,Indices, Red Cell,Mean Cell Volumes,Mean Corpuscular Hemoglobins,Mean Corpuscular Volumes,Size Determination, Erythrocyte,Size Determinations, Erythrocyte,Thickness, Erythrocyte,Volume, Mean Cell,Volume, Mean Corpuscular,Volumes, Mean Cell,Volumes, Mean Corpuscular
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D001172 Arthritis, Rheumatoid A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated. Rheumatoid Arthritis
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective
D012372 ROC Curve A graphic means for assessing the ability of a screening test to discriminate between healthy and diseased persons; may also be used in other studies, e.g., distinguishing stimuli responses as to a faint stimuli or nonstimuli. ROC Analysis,Receiver Operating Characteristic,Analysis, ROC,Analyses, ROC,Characteristic, Receiver Operating,Characteristics, Receiver Operating,Curve, ROC,Curves, ROC,ROC Analyses,ROC Curves,Receiver Operating Characteristics

Related Publications

M Bellan, and D Soddu, and E Zecca, and A Croce, and R Bonometti, and R Pedrazzoli, and D Sola, and C Rigamonti, and L M Castello, and G C Avanzi, and M Pirisi, and P P Sainaghi
June 2015, Clinical chemistry and laboratory medicine,
M Bellan, and D Soddu, and E Zecca, and A Croce, and R Bonometti, and R Pedrazzoli, and D Sola, and C Rigamonti, and L M Castello, and G C Avanzi, and M Pirisi, and P P Sainaghi
March 2018, Mediterranean journal of rheumatology,
M Bellan, and D Soddu, and E Zecca, and A Croce, and R Bonometti, and R Pedrazzoli, and D Sola, and C Rigamonti, and L M Castello, and G C Avanzi, and M Pirisi, and P P Sainaghi
April 2010, Archives of pathology & laboratory medicine,
M Bellan, and D Soddu, and E Zecca, and A Croce, and R Bonometti, and R Pedrazzoli, and D Sola, and C Rigamonti, and L M Castello, and G C Avanzi, and M Pirisi, and P P Sainaghi
October 2023, The Journal of rheumatology,
M Bellan, and D Soddu, and E Zecca, and A Croce, and R Bonometti, and R Pedrazzoli, and D Sola, and C Rigamonti, and L M Castello, and G C Avanzi, and M Pirisi, and P P Sainaghi
November 2012, Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing,
M Bellan, and D Soddu, and E Zecca, and A Croce, and R Bonometti, and R Pedrazzoli, and D Sola, and C Rigamonti, and L M Castello, and G C Avanzi, and M Pirisi, and P P Sainaghi
October 2023, Journal of clinical medicine,
M Bellan, and D Soddu, and E Zecca, and A Croce, and R Bonometti, and R Pedrazzoli, and D Sola, and C Rigamonti, and L M Castello, and G C Avanzi, and M Pirisi, and P P Sainaghi
October 2020, Rheumatology international,
M Bellan, and D Soddu, and E Zecca, and A Croce, and R Bonometti, and R Pedrazzoli, and D Sola, and C Rigamonti, and L M Castello, and G C Avanzi, and M Pirisi, and P P Sainaghi
January 2014, Lower urinary tract symptoms,
M Bellan, and D Soddu, and E Zecca, and A Croce, and R Bonometti, and R Pedrazzoli, and D Sola, and C Rigamonti, and L M Castello, and G C Avanzi, and M Pirisi, and P P Sainaghi
March 2024, Cureus,
M Bellan, and D Soddu, and E Zecca, and A Croce, and R Bonometti, and R Pedrazzoli, and D Sola, and C Rigamonti, and L M Castello, and G C Avanzi, and M Pirisi, and P P Sainaghi
June 2021, Reumatologia clinica,
Copied contents to your clipboard!